Notice 27 Jun 2025 cancer prevention, pharmaceutical, biotechnology, nih, clinical studies, intellectual property

💉NIH Proposes New Intellectual Property Policy for Cancer Research

The National Cancer Institute, an Institute of the National Institutes of Health, Department of Health and Human Services, Division of Cancer Prevention (DCP) is seeking comments on instituting a standard policy on Intellectual Property (IP) developed by certain funding recipients under NCI DCP funding agreements. This standard policy is entitled "The DIVISION OF CANCER PREVENTION INTELLECTUAL PROPERTY OPTION TO COLLABORATORS (IP Option)." The proposed policy, if finalized, shall apply to entities that conduct DCP-funded clinical studies under funding agreements which involve an NCI collaborator that provides its proprietary agent or technology for the DCP-supported studies where this IP Option is included as a term of applicable existing and future funding agreements.

Learn More
Notice 27 May 2025 research, government meetings, veterans affairs, clinical studies

🏛️Notice of Cooperative Studies Scientific Evaluation Committee Meeting

The Department of Veterans Affairs announces a virtual meeting of the Cooperative Studies Scientific Evaluation Committee, where expert advice on VA cooperative studies and clinical research will be provided. The meeting will include a public session followed by a closed session for discussions on research applications and related matters. Attendance details for the open session are provided.

Learn More
Compliance, Regulatory Requirements 7 Jan 2025 regulatory compliance, fda, medical devices, clinical studies, gender-specific data

⚖️FDA Guidance on Sex-Specific Data in Medical Device Studies

The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled "Evaluation of Sex- Specific and Gender-Specific Data in Medical Device Clinical Studies." This document provides guidance on the study and evaluation of sex- and/or gender-specific data in clinical investigations or research involving one or more subjects to determine the safety or effectiveness of a device. The purpose of this guidance is to encourage science- driven consideration of sex and/or gender, as appropriate for both the scientific question being addressed and the intended use of the device, when designing medical device clinical studies and reporting data from such studies in accordance with legal requirements. This draft guidance is not final nor is it for implementation at this time.

Learn More